ENT Technologies partnership

ENT Technologies and Asthma Australia have begun a three-year partnership under which they will work together to improve the respiratory health of Australians with asthma.

As makers of the Flo range of nasal sprays and washes, ENT Technologies says it has much to offer people managing asthma and common associated conditions such as allergic rhinitis (hay fever) and other allergies.

In Australia, one in nine people are affected by asthma, and around 80 per cent of these also suffer from hay fever.

Washing the nose and sinuses with a preservative-free, isotonic saline can help people with asthma and hay fever by reducing the levels of inhaled allergens and viruses inside the nose. This reduces the risk of a severe inflammatory response.

“We are excited about the partnership as we know that our products and philosophy greatly align with Asthma Australia’s mission,” ENT Technologies founder and Medical Director Sam Barbalatt said. “Looking after nasal health is an important part of looking after the respiratory system. All Flo saline products are preservative free and suitable for people with asthma.”

Under the partnership agreement, ENT Technologies will provide funding support to Asthma Australia as well as training asthma educators on the benefits of maintaining nasal health for people with asthma and hay fever.

Asthma Australia CEO Michele Goldman said: “We seek out opportunities to work with organisations who are leaders in their line of work, so that we maximise the support we offer to Australians with asthma, their families and carers.

“We encourage people with asthma to manage hay fever and allergy as part of their asthma care to improve asthma control.

“As well as ENT’s funding commitment, our partnership enables our team to enhance their knowledge and skills, which will ultimately improve the lives of people living with asthma, and their families and carers.”

312FansLike
763FollowersFollow
41FollowersFollow

Must Read

Asthma patients should have flu shot now

PALM breathes new life into asthma

0
World-first drug delivery technology, designed by Monash University researchers to help improve the health of asthmatics, has received a grant of more than $725,000...
X